Clearmind Medicine Initiates First Human Trial for Alcohol Use Disorder
Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use...
Jon Napitupulu
Angitia Biopharmaceuticals Presents Promising Phase 1/2 Study Data of AGA111 at AAOS
Angitia Biopharmaceuticals announced positive Phase 1/2 trial data for AGA111, a recombinant human bone morphogenetic protein 6 (rhBMP6) designed...
Prime Medicine Unveils AATD Gene Correction Treatment Program
Prime Medicine announced a preclinical program for alpha-1 antitrypsin deficiency (AATD), using its prime editing technology delivered via a...
Bio-Path Holdings Announces Promising Pre-clinical Results for BP1001-A in Obesity Treatment for Type 2 Diabetes Patients
Bio-Path Holdings announced positive pre-clinical results for BP1001-A, a potential obesity treatment. The drug candidate successfully reversed fatty acid-induced...
Deramiocel Shows Long-Term Efficacy in Duchenne Muscular Dystrophy Treatment
Capricor Therapeutics announced positive three-year data from its open-label extension of the HOPE-2 clinical trial for deramiocel, a cell-based...
Cellphire Therapeutics gets FDA Fast Track for CLPH-511
Cellphire Therapeutics has received FDA Fast Track Designation for CLPH-511, a frozen activated platelet injectable suspension designed to treat...
PEP-010 Awarded FDA Orphan Drug Status for Pancreatic Cancer
PEP-Therapy’s lead product, PEP-010, a first-in-class bifunctional therapeutic peptide, received Orphan Drug Designation from the FDA for the treatment...
Radiopharm Theranostics: Rad202 Shows Positive Tumor Uptake & Biodistribution
Radiopharm Theranostics presented data at EMIM 2025 demonstrating the effectiveness of RAD202, a HER2-targeting single domain antibody, for both...
Bitterroot Bio Presents Phase 1 BRB-002 Results at ACC.25
Bitterroot Bio will present Phase 1 study results for BRB-002, a novel anti-CD47 therapy for atherosclerotic cardiovascular disease (ASCVD),...
Curevo Raises $110M for Shingles Vaccine
Curevo Vaccine secured $110 million in Series B funding to advance the development of its shingles vaccine, amezosvatein. The...